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Objective: Adequate control of postoperative pain directly improves patient satisfac-
tion and outcomes, and timely identiﬁcation of patients with poorly controlled pain is
essential. Pain management protocols are best studied in patients recovering from the
same operation. In our institution, the postoperative pain regimen for patients undergo-
ing deep inferior epigastric perforator (DIEP) ﬂap breast reconstruction is standardized
using patient-controlled analgesia (PCA) followed by conversion to oral narcotics. From
this uniform population, we were able to identify a subgroup of patients with poor
pain control. Methods: Over a 44-month period, 179 consecutive patients underwent
DIEP ﬂap breast reconstruction with 242 ﬂaps performed. A retrospective chart review
recorded PCA usage, visual analog scale pain scores, and length of stay. Results: Pain
management with PCA after DIEP ﬂap breast reconstruction was uniformly controlled.
Most patients (74.9%) required PCA usage in the ﬁrst 2 days with conversion to oral
analgesics. A subgroup of patients (25.1%) continued to require PCA usage on the third
postoperative day. These “nonresponder” patients had a higher visual analog scale score
on the ﬁrst postoperative day, higher total intravenous morphine use, and a longer length
of stay (all, P <. 05). A multivariate analysis revealed more nonresponders among
patients undergoing immediate breast reconstruction (P <. 05); however, all other fac-
tors analyzed had no correlation. Conclusion: We report a subgroup of patients with
poor pain control after DIEP ﬂap breast reconstruction. This group of patients required
a longer course of pain management and subsequently a longer hospital stay. Pain
management protocols that identify these patients promptly can allow for appropriate
modiﬁcations.
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The proper management of postoperative pain is important in both aesthetic and re-
constructive surgery. It has been shown that when pain is well-controlled, outcomes are
improved in orthopedic, vascular, general, and cardiac surgery.1 Although most patients
achieve proper pain control with a standard regimen, some patients require additional
attention.2 Identiﬁcation of these patients with poor pain control is necessary in the imme-
diate postoperative period, as an individually tailored pain regimen may be required.
Evaluationofpainmanagementprotocolscanbeconfoundedbydifferencesinpopula-
tionschosenforstudy.Ideally,postoperativepainshouldbeassessedincomparablesubjects
undergoing similar, if not identical, operations. Previous studies have shown that patients
with DIEP ﬂap have signiﬁcantly less morphine use and shorter hospitalizations than those
with musculocutaneous ﬂap for breast reconstruction.3,4 For patients undergoing DIEP ﬂap
breast reconstruction at our institution, a standardized pathway has been developed. The
postoperative pain regimen includes patient-controlled analgesia (PCA) for the ﬁrst 3 days,
with conversion to oral narcotics on the morning of the third postoperative day (ie, POD 3).
This regimen was developed with the intention of discharging patients as early as the third
day. All patients underwent the same standardized activity level with transfer to a chair on
the ﬁrst day and ambulation on the second day. Even with this standardization, there are
distinct differences in pain control among different patients and a small group of poorly
controlled patients required additional narcotics.
The acute pain literature describes a population of patients that have a poor response
to narcotic use in both cancer and postsurgical care. These patients represent 25% to
40% of the population and have been previously described as “nonresponders.”5,6 These
patients experience inadequate pain relief or require doses of analgesics that exceed the
standard protocols. Review of the plastic surgery literature revealed few studies examining
postoperative pain in a uniform population.
We evaluated narcotic use and postoperative pain control in patients with DIEP ﬂap
breast reconstruction within a standardized pathway. We used the visual analog score
(VAS) score to assess postoperative pain. The VAS score has been shown to reliably assess
acute pain and changes in pain intensity.7 The goal was to determine the existence of a
nonresponder group and evaluate the characteristics of this subpopulation.
PATIENTS AND METHODS
Over a 44-month period, all patients who underwent autologous breast reconstruction
were identiﬁed. All patients had a DIEP ﬂap reconstruction, as superﬁcial inferior epigas-
tric artery (SIEA), free transverse rectus abdominis musculocutaneous (TRAM), muscle-
sparing free TRAM, and pedicled TRAM ﬂaps were excluded. Details of the operative
technique were standardized including the internal mammary recipient vessel site as well
as the abdominal closure; no patients in this series required abdominal mesh placement.
A retrospective chart review of the clinical course, postoperative PCA usage, VAS
pain scores, and length of stay was performed. The VAS score was recorded as a daily
average. Patients were excluded if there was a return to the operating room, as this altered
the standardized pain control regimen. Patients were evaluated the morning of the POD 3
for conversion to oral narcotics. Criteria for conversion to an oral regimen were based on a
low overnight VAS score with minimal overnight PCA morphine usage.
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Figure 1. Daily median visual analog scale (VAS) scores for the study population in the ﬁrst 3
postoperative days (n = 179).
A detailed database was reviewed, and data collection included patient demographics,
body mass index (BMI), Breast Cancer susceptibility gene (BRCA) status, previous radi-
ation, previous chemotherapy, immediate/delayed reconstruction, unilateral/bilateral, ﬂap
weight, mastectomy weight, recipient vessel, number of perforators, and microvascular ﬂap
complications.
Patients were categorized as responders if they were successfully weaned from PCA
opioids to oral pain medications by the POD 3. Comparisons of intravenous (IV) morphine
requirements, VAS scores, and length of stay were analyzed by using the Mann-Whitney
U test. Comparisons of incidences were performed using a Fisher exact test. Univariate
analysis of factors associated with nonresponders was performed; all factors that were
found to be signiﬁcant to the P ≤ .25 level were included in multiple logistic regression
analyses. Multiple logistic regression with nonresponder status as the dependent variable
was performed using backwards stepwise elimination with elimination signiﬁcance set
to .10. Statistical signiﬁcance was determined at P ≤ .05.
The study was approved by the institutional review board at Beth Israel Deaconess
Medical Center.
RESULTS
Over a 44-month period, 179 consecutive patients underwent DIEP ﬂap breast reconstruc-
tion with a total of 242 ﬂaps performed. All patients received PCA in the ﬁrst 3 PODs: 133
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patients received morphine and 46 patients received hydromorphone. The hydromorphone
dose was converted to morphine with a 5-to-1 conversion.8
Figure 2. Number of patients requiring PCA for each POD. Patients requiring PCA on POD 3
were identiﬁed as nonresponders (45/179, 25.1%). PCA indicates patient-controlled analgesia;
POD, postoperative day.
The median VAS scores during the ﬁrst 3 PODs revealed that pain was well-controlled
for the population as a whole (Fig 1). When analyzing the PCA usage over the ﬁrst 3
PODs (Fig 2), most patients (134, 74.8%) required PCA usage only in the ﬁrst 2 days and
were quickly converted to oral pain medication. However, a small group of patients (45,
25.1%) was identiﬁed, which continued to require PCA usage on the POD 3. This group of
nonresponders had a signiﬁcantly higher VAS score on POD 1 (5 vs 4 p < 0.05) (Fig 3).
In addition, this population had a signiﬁcantly higher total IV morphine consumption
(95 ± 70 mg vs 70 ± 50 mg, P <. 05) (Fig 4) and a longer length of stay (4.75 vs 4.2 days,
P <. 05) (Table 1) than the responders group.
We also found a relationship between the VAS score on POD 1 and the total IV
morphine consumption (Fig 5). A higher VAS score on POD 1 was associated with a higher
total PCA morphine use for the entire hospitalization. Nonresponders were more likely to
have a VAS score of ﬁve or more on POD 1 than responders (40% vs. 20%; P < 0.05).
This resulted in a positive predictive value of 39% and a negative predictive value of 81%.
Amultivariatelogisticregressionanalysiswasperformedidentifyingfactorsthatmight
inﬂuence postoperative analgesia requirements. There was a statistically higher percentage
of patients undergoing immediate reconstruction in the nonresponders group compared to
delayed reconstruction (29.5% [36/122] vs 15.8% [9/57], P <. 05). There were no other
correlations for age, BMI, BRCA status, a previous history of radiation or chemotherapy,
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mastectomy weight, ﬂap weight, and unilateral versus bilateral reconstruction (Table 1).
There was no correlation for number of perforators used as well.
DISCUSSION
The DIEP ﬂap breast reconstruction population represents a uniform group of patients
amenable to speciﬁc evaluation of postoperative pain. With the standardization of pain
treatment, identiﬁcation of factors contributing to pain control can be extracted. Analysis
ofthedatademonstratedthatonthePOD3themajorityofpatientsnolongerrequiredPCA.
On the basis of VAS scores, these patients, the “responder” group, had a normal response
to narcotics with well-controlled pain. This reinforced the efﬁcacy of our postoperative
pathway for DIEP ﬂap breast reconstruction—most patients quickly converted to oral
narcotics and were discharged home uneventfully.
We found a distinct nonresponder subgroup of patients who had elevated pain scores
despite higher PCA consumption. This group was characterized by a signiﬁcantly higher
VAS score on the POD 1, a greater total IV morphine consumption, and a longer hospital
stay. In addition, their VAS score and daily morphine usage were higher than those of the
responder group. Multivariate analysis revealed that a higher percentage of these patients
had an immediate breast reconstruction.
Figure 3. A comparison of average visual analog scale (VAS) scores on each postopera-
tive day between responder (blue) and nonresponder (red) groups. Nonresponders were more
likely to have a VAS score 5 or more on the ﬁrst postoperative day (POD 1) than responders
(5 vs 4, P <. 05).
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Figure 4. A comparison of daily morphine requirement between responder (blue) and
nonresponder (red) groups. Nonresponders had a signiﬁcantly higher total intravenous (IV)
morphine consumption (95 ± 70 mg vs 70 ± 50 mg, P <. 05).
Stameretal5 weretheﬁrsttoidentifyasubgroupofnonresponderswhohadhigherpain
scores and required more analgesic consumption than their “normal” counterparts. Other
studieshavesuggestedthatvarianceinpostoperativepaincontrolcouldresultfromdifferen-
tial pain receptor densities among patients. Patients typically demand more analgesia from
a PCA, as their plasma concentration drops below a minimum effective concentration.9
This concentration shows considerable variation between patients, suggesting that there
may be constitutional sensitivity differences at the level of the opioid receptors. The
μ-opioid peptide receptor (MOP) has been identiﬁed as the principal site for pharma-
cologic action of most clinically important opiate drugs. Recent studies using various
knockout mice and recombinant-inbred strain CXBK mice models have indicated that the
analgesiceffectofmorphineisdirectlydependentonMOPdensities.10 Therearemorethan
100 polymorphisms identiﬁed in the human MOP (OPRM1) gene which could explain the
interindividual differences in pain control by opiate analgesia.10
Stamer et al5 reported a higher rate of nonresponders (40%) than our study group
(25.2%). This could be attributed to differences in study design, as they evaluated patients
undergoing multiple types of operations. Their nonresponder group included a higher
proportion of patients undergoing major abdominal surgery than the responders group.
In our study design, a homogeneous patient population was identiﬁed. Both groups were
similar in operative detail and extent (number of perforators, unilateral versus bilateral,
mastectomyweightandﬂapweight).Ourpercentageofnonrespondersisclosertotheknown
variability described in cancer patients. The acute pain literature describes a nonresponder
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population in patients treated with narcotics for pain related to cancer. In this population,
20% to 34% of patients had a clinical failure to narcotics requiring a change in pain
management.6,11
Table 1. Comparison of Responder and Nonresponder Groups
Responders (n = 134) Nonresponders (n = 45) P
Patient characteristics
Age, mean ± SD, y 47.5 ± 8.0 47.9 ± 7.8 .78
Mastectomy weight, mean ± SD, g 696 ± 371 654 ± 309 .56
Flap weight, mean ± SD, g 652 ± 264 679 ± 207 .48
BRCA genetic mutation 13% (n = 18) 13% (n = 6) 1.0
Radiation therapy 26% (n = 35) 24% (n = 11) 1.0
Chemotherapy 19% (n = 26) 11% (n = 5) .26
Bilateral 34% (n = 46) 40% (n = 18) .59
Delayed 64% (n = 86) 80% (n = 36) .64
Body Mass Index, mean ± SD, kg/m2 26.5 ± 5.0 27.0 ± 5.0 .54
Length of stay, d 4.2 4.75 P <. 05∗
Postoperative pain characteristics
Visual analog scale score 4/10 (2-5) 5/10 (3-5) P <. 05∗
Total intravenous morphine, mg 70 ± 50 95 ± 70 P <. 05∗
∗ Visual analog scale score represents the mean score during the ﬁrst 3 days. Total intravenous morphine represents the
total morphine usage over the ﬁrst 3 days. Mann-Whitney U test for statistical analysis.
Figure 5. Visual analog scale (VAS) score on the ﬁrst postoperative day (POD 1) relative to the
total intravenous morphine consumption over the entire hospitalization.
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Our study revealed that a nonresponder could be predicted on the POD 1 by a signiﬁ-
cantly higher VAS score. Previous studies were able to identify 89.2% of the nonresponders
based on the size of the loading dose and the pain scores in the ﬁrst 30 minutes after
surgery.5 Others studies have also shown the importance of the loading dose in predict-
ing postoperative analgesia requirements. Butscher et al12 used the initial IV bolus dose
to predict the need for intermittent intramuscular injections after surgery. Macintyre and
Jarvis showed in 78 postoperativepatientsthat pain scores and loading dose correlated with
morphine consumption during the ﬁrst 24 hours.13
The ability to predict the nonresponder patients in the POD 1 is extremely important.
As the nonresponder group consumes higher total morphine amounts, they experience
poor pain control at the same time. Reducing the opioid dose has been shown to decrease
the opioid-related side effects (nausea, dizziness, fatigue, sleep disturbance, and ileus).14
Improvements in pain control combined with a reduction in side effects can directly affect
the length of stay. We found this to be signiﬁcant as the length of stay was longer in our
nonresponder group (4.75 vs 4.2 days, P < .05).
With early detection of nonresponders, we can potentially improve postoperative pain
management by combining different types of systemic analgesics. The major beneﬁt of
multimodalanalgesiamaybeadecreaseintheincidenceofopioidsideeffectsratherthanan
increase in the effectivenessof pain control.1 In addition,early interventionmay potentially
decrease length of stay. The addition of gabapentin in the postoperative pain regimen has
been shown to reduce postoperative narcotic use, and further studies evaluating efﬁcacy
in this subgroup are underway.15 Finally, the use of continuous local anesthetic infusion
pain pumps has been described for use in breast reconstruction recently and may represent
another modality for pain control in this population.16-19
Our study has several limitations. As our postoperative pain data was collected using
IVPCA,itisnotclearhowpainiscomparablycontrolledonoralpainmedications.Itwould
be important to determine whether a similar nonresponder group exists for oral opioids.
With the shift of many plastic surgery procedures to an outpatient setting, identiﬁcation
and intervention in this subset of patients could potentially improve postoperative care on
a wider scale. Another limitation is the psychological response to postoperative pain. As
there are emotional and learned responses to pain, further collaborations are necessary to
evaluate these associated psychological components.
The last limitation is that there are minute technical differences even among DIEP
ﬂap reconstruction patients. As the amount of muscle dissection and nerve damage can be
variable based on the anatomy, this can affect postoperative pain. Our study did not ﬁnd
associations between number of perforators used and pain; however, nerve damage and
injury can be difﬁcult to quantify and can certainly contribute to postoperative pain.
The presence of a nonresponder group is important in any postsurgical setting. As
opioid receptor characteristics are universal, recognition of this subgroup is critical and
not conﬁned to one type of surgery.5 Postoperative pain is relevant in all aspects of plastic
surgery from aesthetic to reconstructive surgery. Proper evaluation of different uniform
postoperative populations is necessary to correlate with our ﬁndings. If nonresponders can
be detected as early as the ﬁrst postoperative hour, their pain regimen can be adjusted
accordingly and may improve their postoperative course.5 More precise studies on the
relationship between gene polymorphisms and opioid sensitivity can one day individualize
unique pain management protocols for every patient.
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CONCLUSION
Our study identiﬁes a group of patients who have a poor response to standardized pain
control regimens after a DIEP ﬂap breast reconstruction. This group of nonresponders
requires more IV PCA morphine and has a longer length of stay. We can identify these
patients on the basis of the VAS score on the POD 1 and can potentially alter their pain
management and improve patient outcomes. We hope to design future prospective trials to
address this group.
REFERENCES
1. Bonnet F, Marret E. Inﬂuence of anaesthetic and analgesic techniques on outcome after surgery. Br J
Anaesth. 2005;95(1):52-8.
2. Hess PE, Pratt SD, Lucas TP, et al. Predictors of breakthrough pain during labor epidural analgesia. Anesth
Analg. 2001;93(2):414-18.
3. GillPS,HuntJP,GuerraAB,etal.A10-yearretrospectivereviewof758DIEPﬂapsforbreastreconstruction.
Plast Reconstr Surg. 2004;113(4):1153-60.
4. Kroll SS, Sharma S, Koutz C, et al. Postoperative morphine requirements of free TRAM and DIEP ﬂaps.
Plast Reconstr Surg. 2001;107(2):338-41.
5. Stamer UM, Grond S, Maier C. Responders and non-responders to post-operative pain treatment: the
loading dose predicts analgesic needs. Eur J Anaesth. 1999;16(2):103-10.
6. Enting RH, Oldenmenger WH, van der Rijt CC, et al. A prospective study evaluating the response of
patients with unrelieved cancer pain to parenteral opioids. Cancer. 2002;94(11):3049-56.
7. Breivik H, Borchgrevink PC, Allen SM, et al. Assessment of pain. Br J Anaesth. 2008;101(1):17-24.
8. Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphine and hydromorphone in patients with
cancer pain: a retrospective study. Pain. 1997;72(1/2):79-85.
9. Tamsen A, Hartvig P, Dahlstrom B, Wahlstrom A, Terenius L. Endorphins and on-demand pain relief.
Lancet. 1980;1(8171):769-70.
10. Nagashima M, Katoh R, Sato Y, Tagami M, Kasai S, Ikeda K. Is there genetic polymorphism evidence for
individual human sensitivity to opiates? Curr Pain Headache Rep. 2007;11(2):115-23.
11. Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for
Palliative Care. BMJ. 1996;312(7034):823-6.
12. Butscher K, Mazoit JX, Samii K. Can immediate opioid requirements in the post-anaesthesia care unit be
used to determine analgesic requirements on the ward? Can J Anaesth. 1995;42(6):461-6.
13. Macintyre PE, Jarvis DA. Age is the best predictor of postoperative morphine requirements. Pain.
1996;64(2):357-64.
14. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician.
2006;74(8):1347-54.
15. HoKY,GanTJ,HabibAS.Gabapentinandpostoperativepain:asystematicreviewofrandomizedcontrolled
trials. Pain 2006; 126(1-3):91-101.
16. Heller L, Kowalski AM, Wei C, Butler CE. Prospective, randomized, double-blind trial of local anesthetic
infusionandintravenousnarcoticpatient-controlledanesthesiapumpforpainmanagementafterfreeTRAM
ﬂap breast reconstruction. Plast Reconstr Surg. 2008; 122(4):1010-18.
17. Boehmler JH, Venturi ML, Nahabedian MY. Decreased narcotic use with an implantable local anesthetic
catheter after deep inferior epigastric perforator ﬂap breast reconstruction. Ann Plast Surg. 2009;62(6):618-
20.
18. Rawlani V, Kryger ZB, Lu L, Fine NA. A local anesthetic pump reduces postoperative pain and narcotic
and antiemetic use in breast reconstruction surgery: a randomized control trial. Plast Reconstr Surg. 2008;
122(1):39-52.
19. Losken A, Parris JJ, Douglas TD, Codner MA. Use of the infusion pain pump following transverse rectus
abdominis muscle ﬂap breast reconstruction. Ann Plast Surg. 2005;54(5):479-82.
491